Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy

URN to cite this document:: urn:nbn:de:bvb:355-epub-545850
DOI to cite this document:: 10.5283/epub.54585

Kleber, Julia ; Yang Zhou, Jordi ; Weber, Florian

; Bitterer, Florian

; Hauer, Patricia ; Kupke, Paul

; Kronenberg, Katharina ; Geissler, Edward K.

; Schlitt, Hans J.

; Hornung, Matthias

; Hutchinson, James A.

; Werner, Jens M.

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 17 Aug 2023 05:28

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal carcinomatosis (PC) from colorectal cancer (CRC), which is otherwise a terminal stage of disease. Nevertheless, survival outcomes are only marginally superior to other treatments. This fact highlights the need for better strategies to control intra-abdominal disease ...